For full functionality of this website it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser

Session Details

ROUNDTABLE Exosome Therapeutics: Are MSCs now Redundant?
Wednesday, May 31, 2023 09:15 AM - 10:15 AM  
Room 241
Clinic & the Lab
Roundtable
Debate manufacturing and regulatory advantages of MSC-Exosomes versus MSCs.

Moderator
Daniel Gau, MSc, VP Product Development, 2 Bridge, Belgium

Panelists
Manoj Lalu, MD, PhD, FRCPC, Associate Professor, Scientist, The Ottawa Hospital Research Institute, Canada
Sai Kiang Lim, PhD, A*STAR Institute of Molecular and Cell Biology, Singapore
Jan Nolta, PhD, Professor, University of California, Davis, USA
Bernd Giebel, PhD, Professor, University of Duisburg-Essen, Germany



Session Description
MSC-exosomes have been shown to mediate many MSC therapeutic activities and MSC-exosomes have been positioned as a therapeutic to replace MSCs. This session provides a platform to debate this positioning.


Learning Objectives:
  1. Compare and contrast the therapeutic advantages of mesenchymal stem cells (MSCs) and extracellular vesicles (EVs) from a biological perspective. Discuss the potential value of these advantages in specific therapeutic applications.
  2. Evaluate the common hurdles associated with the clinical translation of both MSCs and EVs, including challenges related to starting materials, manufacturing, and regulatory approval. Propose potential solutions to overcome these hurdles.

Daniel Gau MSc
VP Product Development
2 Bridge
Moderator


Bernd Giebel PhD
Professor
University Duisburg-Essen
Panelist


Manoj Lalu MD, PhD, FRCPC
Associate Professor, Scientist
The Ottawa Hospital Research Institute
Panelist


Sai Kiang Lim PhD
A*STAR Institute of Molecular and Cell Biology
Panelist


Jan Nolta PhD
Professor
University of California, Davis
Panelist